Loading company…
Samsara Therapeutics develops autophagy-activating drugs for age-related neurodegenerative diseases such as Alzheimer's.
Founded in 2018 and headquartered in Hamburg, Germany, Samsara Therapeutics focuses on therapeutics that activate autophagy, with drug candidates aimed at slowing the progression of Alzheimer's and Parkinson's. Its most recent funding round, a USD 25 mn Series A led by Apollo Health Ventures, occurred on September 6, 2022. Its revenue model relies on pharmaceutical collaboration agreements, funding from patient advocacy groups and potential licensing deals.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in